Annals of Oncology 12:S43-S47, 2001
© 2001 European Society for Medical Oncology
Symposium Article |
Pharmacologic insights into the future of trastuzumab
1 Department of Oncology, McGill University Montreal
2 Hamilton Regional Cancer Centre Hamilton
3 BCCA Vancouver Centre Vancouver
4 Ottawa Regional Cancer Centre Ottawa, Canada
5 Memorial Sloan Kettering Cancer Center New York, USA
6 F. Hoffmann-La Roche Ltd Toronto, Canada
7 F. Hoffmann-La Roche Ltd Welwyn Garden City, UK
8 F. Hoffmann-La Roche Ltd Basel, Switzerland
Correspondence to: B. Leyland-Jones, MD Department of Oncology McGill University 546 Pine Avenue West Montreal H2W 1S6 Canada E-mail: leylandj{at}med.mcgill.ca
A combination of factors has been responsible for improvements in cancer survival and cure rates. In addition to new therapies with novel/genetic targets, these include improvements in drug delivery, new schedules/sequencing of drug administration and the identification of combination therapies with greater activity/dose density than existing regimens. The recognition that such criteria can affect treatment outcome has led to their incorporation into clinical trials of new drugs. Furthermore, pharmacokinetic and pharmacodynamic parameters have become increasingly important for the rational selection of dose, administration route and schedule. The humanized monoclonal antibody trastuzumab (Herceptin) has been rationally developed to target the human epidermal growth factor receptor-2 (HER2), which is overexpressed in 20%–30% of breast cancers and is associated with poor prog-nosis. Trastuzumab when administered i.v. on a weekly schedule either alone or in combination with taxanes, improves survival of women with HER2-positive metastatic breast cancer. Based upon pharmacokinetic considerations, current studies are examining whether trastuzumab can be administered i.v. every three weeks or by the s.c. route. These regimens would have advantages for patients and medical staff in terms of acceptability, ease of administration and, potentially, cost effectiveness. Furthermore, various combinations of trastuzumab and chemotherapeutic agents are being explored with the aim of identifying the optimal combination regimen for clinical use. The rationale for these various studies and the studies themselves are described.
combination therapy, HER2, Herceptin, intravenous, pharmacokinetics, subcutaneous, trastuzumab
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. E. Bremner, C. A. K. Y. Chong, G. Tomlinson, S. M. H. Alibhai, and M. D. Krahn A Review and Meta-Analysis of Prostate Cancer Utilities Med Decis Making, May 1, 2007; 27(3): 288 - 298. [Abstract] [PDF]
|
|
|
|
 |
|
 F. Montemurro, M. Donadio, M. Clavarezza, S. Redana, M. E. Jacomuzzi, G. Valabrega, S. Danese, G. Vietti-Ramus, A. Durando, M. Venturini, et al. Outcome of Patients with HER2-Positive Advanced Breast Cancer Progressing During Trastuzumab-Based Therapy. Oncologist, April 1, 2006; 11(4): 318 - 324. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T.-H. Huang and S. L. Morrison A Trimeric Anti-HER2/neu ScFv and Tumor Necrosis Factor-{alpha} Fusion Protein Induces HER2/neu Signaling and Facilitates Repair of Injured Epithelia J. Pharmacol. Exp. Ther., March 1, 2006; 316(3): 983 - 991. [Abstract] [Full Text] [PDF]
|
|